Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32866432

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Oct
First author
Kumar SK

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Dec;21(12):e540. doi: 10.1016/S1470-2045(20)30635-5.
    note
    Source null
    related pmid
    33271097
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Dec;21(12):e541. doi: 10.1016/S1470-2045(20)30695-1.
    note
    Source null
    related pmid
    33271098
    relationship
    Comment in

Authors and identifiers

  1. name
    Kumar SK
    type
    Author
  2. name
    Jacobus SJ
    type
    Author
  3. name
    Cohen AD
    type
    Author
  4. name
    Weiss M
    type
    Author
  5. name
    Callander N
    type
    Author
  6. name
    Singh AK
    type
    Author
  7. name
    Parker TL
    type
    Author
  8. name
    Menter A
    type
    Author
  9. name
    Yang X
    type
    Author
  10. name
    Parsons B
    type
    Author
  11. name
    Kumar P
    type
    Author
  12. name
    Kapoor P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kumar SK
    type
    Author
  2. name
    Jacobus SJ
    type
    Author
  3. name
    Cohen AD
    type
    Author
  4. name
    Weiss M
    type
    Author
  5. name
    Callander N
    type
    Author
  6. name
    Singh AK
    type
    Author
  7. name
    Parker TL
    type
    Author
  8. name
    Menter A
    type
    Author
  9. name
    Yang X
    type
    Author
  10. name
    Parsons B
    type
    Author
  11. name
    Kumar P
    type
    Author
  12. name
    Kapoor P
    type
    Author
bibliography ids
  1. nci-bib-eb9b8887f1fd307d27ad7baf
book metadata
content sha256
0656651e2b2aa350e026a5a10d04566d04d7932256252b367402aca80014446b
document type
citation
dois
  1. 10.1016/S1470-2045(20)30452-6
electronic publication date
display
2020 Aug 28
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32866432
immutable id
pubmed:32866432@0656651e2b2aa350e026a5a10d04566d04d7932256252b367402aca80014446b
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1317-1330
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Dec;21(12):e540. doi: 10.1016/S1470-2045(20)30635-5.
    note
    Source null
    related pmid
    33271097
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Dec;21(12):e541. doi: 10.1016/S1470-2045(20)30695-1.
    note
    Source null
    related pmid
    33271098
    relationship
    Comment in
outcomes validated
false
pmid
32866432
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
31f300a57aa13a52bef4f01e38febe2273b6031b920ac404e38e7cb9ecc97512
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Oct
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32866432/
title
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Preserved source evidence · Not medical advice